Ikarugamycin

Ikarugamycin (CAS No.: 36531-78-9) is a macrocyclic antibiotic natural product isolated from Streptomyces species that is widely utilized as a chemical probe in cell biology and drug discovery research due to its potent inhibition of clathrin-mediated endocytosis (CME). By disrupting the formation of clathrin-coated pits and vesicles at the plasma membrane, ikarugamycin effectively blocks receptor internalization and membrane protein trafficking, making it a valuable tool for dissecting vesicular transport mechanisms and endocytic pathway regulation. In addition to its role as an endocytosis inhibitor, ikarugamycin exhibits antimicrobial and antiprotozoal activities and demonstrates cytotoxic effects in cancer cell models, where it suppresses cell proliferation in the nanomolar to low micromolar range through mechanisms involving genotoxic stress, induction of apoptosis, and activation of caspase signaling pathways. It has also been reported to modulate lipid metabolism in macrophages by inhibiting oxidized low-density lipoprotein-induced cholesteryl ester accumulation, suggesting broader impacts on cellular metabolic processes. In research settings, ikarugamycin is commonly applied to investigate receptor trafficking, signal transduction, and intracellular uptake pathways, as well as to evaluate the dependence of therapeutic candidates on CME for cellular entry, with experimental concentrations typically tailored to specific assay conditions and biological contexts.